Canaccord Genuity Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $20
Portfolio Pulse from jenniferd'souza@benzinga.com
Canaccord Genuity analyst Sumant Kulkarni maintains a 'Buy' rating on BioXcel Therapeutics (NASDAQ:BTAI) but has lowered the price target from $75 to $20.
August 15, 2023 | 11:56 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
BioXcel Therapeutics' price target has been lowered from $75 to $20 by Canaccord Genuity, though the 'Buy' rating is maintained.
The significant reduction in the price target for BioXcel Therapeutics by Canaccord Genuity could negatively impact investor sentiment and potentially lead to a short-term decrease in the stock price. However, the maintained 'Buy' rating indicates that the analyst still sees potential in the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100